Shares of Danish biotech Saniona AB (STOCKHOLM:SANION) closed at SEK36.65 (US$4.05) for a gain of SEK8.95 (US$.99), or 32.3 percent, Monday after partner Productos Medix S.A. de C.V. reported statistically and clinically significant weight loss for both doses of tesofensine compared to placebo in the phase III VIKING study in obesity. Medix will use the findings, which included good tolerability with a low incidence of adverse events, for filings in Mexico and Argentina, where it owns commercial rights.